The Dow Chemical Company

Biogen Idec Ma Inc.

Memorial Sloan Kettering Cancer Center

Ludwig Institute for Cancer Research Limited

Medarex Inc.

Biogen, Incorporated

Frank J Carr

Philip Ronald Tempest

William Joseph Harris

W H Kerr Anderson

Kathryn Armour

Roy R Lobb

Lloyd J Old

Sydney Welt

Kunio Kitamura

T Paul Wallace

The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites of inflammation.

Recombinant anti-VLA4 antibody molecules

Treatment for asthma with &#x3b1;4-specific antibodies

Treatment for inflammatory bowel disease with &#x3b1;4-specific antibodies

Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.

High affinity humanized anti-TAG-72 monoclonal antibodies

High affinity humanized anti-Tag-72 monoclonal antibodies

High affinity humanized anti-tag-72 monoclonalantibodies

Recombinant anti-VLA-4 antibody molecules

Humanized antibodies are described which are specific to an Fc receptor (FcR). The humanized antibodies have at least a portion of a complementarity determining region (CDR) derived from a non-human antibody, e.g., murine, with the remaining portions being human in origin. The humanized antibodies can be used therapeutically as is or formulated as bifunctional molecules or immunotoxins.

Humanized antibodies to Fc receptors for immunoglobulin G on human mononuclear phagocytes

Novel humanized monoclonal antibodies, fragments or derivatives thereof which specifically bind carcinoembryonic antigen (CEA) are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express CEA as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express CEA.

High affinity humanized anti-CEA monoclonal antibodies

High affinity humanized anti-TAG-72 monoclonalantibodies

The invention provides for the production of several humanized murine antibodies specific for the Lewis b antigen, which is recognized by the murine antibody 58-1066. The antigen is expressed on cell lines from colon, lung, bladder, breast, renal, pancreatic and ovarian cancers. The expression of the antigen is greatly increased in cancer tissues as compared to its expression in the corresponding normal tissue. The invention also provides for numerous polynucleotide encoding humanized Lewis b antigen specific antibodies, expression vectors for producing humanized Lewis b antigen specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized Lewis b antigen specific antibodies. Additionally, the invention provides methods of treating cancer using Lewis b antigen specific antibodies.

Isolated nucleic acid molecules which encode human anti-Lewis b

Growing community of inventors

Balmedie, United Kingdom

Frank J Carr